Pushko, P, Tumpey, TM, Bu, F, Knell, J, Robinson, R and Smith, G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23: 5751-5759

Novavax, Inc., Vaccine Technologies, 1 Taft Court, Rockville, MD 20850, USA.
Vaccine (Impact Factor: 3.62). 01/2006; 23(50):5751-9. DOI: 10.1016/j.vaccine.2005.07.098
Source: PubMed


Avian influenza viruses represent a growing threat for an influenza pandemic. To develop recombinant vaccine for avian influenza of the H9N2 subtype, we expressed in insect cells virus-like particles (VLPs) consisting of three structural proteins of influenza A/Hong Kong/1073/99 (H9N2) virus. Upon infection of Sf9 cells with recombinant baculoviruses, the hemagglutinin (HA), neuraminidase (NA), and matrix (M1) proteins were co-expressed in the infected cells, self-assembled, and released into the culture medium as VLPs of 80-120nm in diameter. VLPs exhibited functional characteristics of influenza virus including hemagglutination and neuraminidase activities. In BALB/c mice, VLPs elicited serum antibodies specific for influenza A/Hong Kong/1073/99 (H9N2) virus and inhibited replication of the influenza virus after challenge. Thus, VLPs represent a potential strategy for the development of human vaccines against avian influenza H9N2 viruses.

Download full-text


Available from: Gale Smith, Oct 13, 2014
98 Reads
  • Source
    • "Influenza VLPs have been generated by co-infecting insect cells with recombinant baculoviruses expressing structural influenza proteins of matrix 1 (M1)/hemagglutinin (HA), HA/neuraminidase (NA)/M1, or HA/NA/M1/matrix 2 (M2). [14,15,21,28,33]. Influenza VLPs have been found to induce protective immunity in preclinical and clinical studies [20]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Infectious bronchitis virus (IBV) poses a severe threat to poultry industry and causes heavy economic losses worldwide. Vaccination is the most effective ways of preventing the infection and controlling the spread of IBV, but the currently available inactivated and attenuated virus vaccines have some disadvantages. We have developed a chimeric virus-like particle (VLP)-based candidate vaccine for IBV protection. The chimeric VLP was composed of M1 protein from avian influenza H5N1 virus and a fusion protein NA/S1 that was generated by fusing IBV S1 protein to the cytoplasmic and transmembrane domains of NA protein of avian influenza H5N1 virus. The chimeric VLPs elicited significant higher S1-specific antibody responses in intramuscularly immunized mice and chickens than inactivated IBV viruses. Furthermore, the chimeric VLPs induced significantly higher neutralization antibody levels than inactivated H120 virus in SPF chickens. In addition, the chimeric VLPs induced significantly higher IL-4 production in mice. These results demonstrated that the chimeric VLPs have the potential for further development of vaccines against IBV infection.
    Journal of veterinary science (Suwŏn-si, Korea) 12/2013; 15(2). DOI:10.4142/jvs.2014.15.2.209 · 1.16 Impact Factor
  • Source
    • "Recent studies have demonstrated that H5N1, H3N2 and H9N2 VLP vaccines comprised of only three influenza virus proteins, hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) can be expressed in insect cells. These vaccines elicited high-titer antibodies and protected against challenge with lethal viruses (Bright et al., 2007, 2008; Pushko et al., 2005). In addition, VLPs containing the influenza glycoprotein HA and the influenza matrix protein M1 induced high titers of virus-specific antibodies in vaccinated mice or ferrets and provided immunized animals with protection against otherwise lethal experimental infections (Ross et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Avian influenza virus (AIV) and Newcastle disease virus (NDV) are both important pathogens in poultry worldwide. The protection of poultry from avian influenza and Newcastle disease can be achieved through vaccination. We embarked on the development of a bivalent vaccine that would allow for a single immunization against both avian influenza and Newcastle disease. We constructed a chimeric virus-like particle (VLP) that is composed of the M1 protein and HA protein of avian influenza virus and a chimeric protein containing the cytoplasmic and transmembrane domains of AIV neuraminidase protein (NA) and the ectodomain of the NDV hemagglutinin-neuraminidase (HN) protein (NA/HN). The single immunization of chickens with the chimeric VLP vaccine induced both AIV H5- and NDV-specific antibodies. The HI titers and specific antibodies elicited by the chimeric VLPs were statistically similar to those elicited in animals vaccinated with the corresponding commercial monovalent vaccines. Chickens vaccinated with chimeric VLP vaccine and then challenged with the Newcastle disease F48E9 virus displayed complete protection. Overall, the chimeric VLP vaccine elicits strong immunity and can protect against Newcastle disease virus challenge.
    Virus Research 09/2013; 178(2). DOI:10.1016/j.virusres.2013.09.009 · 2.32 Impact Factor
  • Source
    • "The genes were codon optimized for optimal expression in insect cells and biochemically synthesized for A(H5N1) HA, NA, M1 (Geneart AG, Regensburg, Germany); and for A(H7N9) and A(H7N3) HA and NA genes (Genscript, Piscataway, NJ). Influenza VLP were produced using full length, HA and NA genes specific for each strain combined with common influenza A/Indonesia/05/2005 M1 as described [10] [11]. Full length HA, NA, and M1 genes were cloned between BamHI–HindIII sites in pFastBac1 baculovirus transfer vector plasmid (Invitrogen, Carlsbad, CA) such that each gene was under the transcriptional control of the Autographa californica multiple nuclear polyhedrosis virus (AcMNPV) polyhedrin promoter. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The recent emergence of severe human illness caused by avian-origin influenza A(H7N9) viruses in China has precipitated a global effort to rapidly develop and test vaccine candidates. To date, non-A(H7N9) H7 subtype influenza vaccine candidates have been poorly immunogenic and difficulties in production of A(H7N9) virus seed strains have been encountered. A candidate recombinant A(H7N9) vaccine consisting of full length, unmodified hemagglutinin (HA) and neuraminidase (NA) from the A/Anhui/1/2013 and the matrix 1 (M1) protein from the A/Indonesia/05/2005 (H5N1) were cloned into a baculovirus vector. Baculovirus infected Spodoptera frugiperda (Sf9) insect cells secreted virus like particles (VLP) composed of HA, NA, and M1 that resemble mature influenza virions. Genetic construction of vaccine from acquisition of an H7N9 genomic sequence to production of A(H7N9) VLP occurred in 26 days. The immunogenicity and efficacy of A/Anhui/1/2013 (H7N9) VLP vaccine administered on days 0 and 14 were evaluated in a lethal wild-type challenge Balb/c mouse model. Control groups included a non-homologous H7 vaccine (A/chicken/Jalisco/CPA1/2012 (H7N3)-VLP), and A/Indonesia/05/2005 (H5N1)-VLP, or placebo. All vaccines were administered with or without ISCOMATRIX. A(H7N9) VLP elicited hemagglutination-inhibition (HAI) antibody titers of ≥1:64 against the homologous virus, cross-reactive HAI against the heterologous A(H7N3), and 3- to 4-fold higher HAI responses in corresponding ISCOMATRIX subgroups. Similarly, all doses of H7N9 VLP elicited anti-neuraminidase (NA) antibody, with 3- to 4-fold higher responses measured in the corresponding ISCOMATRIX subgroups. The non-homologous H7 vaccine induced both H7N3 and H7N9 HAI but no N9 anti-NA antibodies. A lethal murine wild-type A/Anhui/1/2013 (H7N9) challenge demonstrated 100% survival of all animals receiving A(H7N9) and A(H7N3) vaccine, versus 0% survival in A(H5N1) vaccine and placebo groups. Together, the data demonstrate that recombinant H7N9 vaccine can be rapidly developed that was immunogenic and efficacious supporting testing in man as a pandemic influenza H7N9 vaccine candidate.
    Vaccine 07/2013; 31(40). DOI:10.1016/j.vaccine.2013.07.043 · 3.62 Impact Factor
Show more